| 1. |
Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on[J]. Lancet, 2017, 390(10092): 415-423.
|
| 2. |
The White House. The precision medicine initiative[Z]. 2015.
|
| 3. |
Wen Y, Wan Z, Ren H, et al. Interpretable machine learning model for predicting and assessing the risk of diabetic nephropathy: prediction model study[J]. JMIR Med Inform, 2025, 13: e64979.
|
| 4. |
Krzyszczyk P, Acevedo A, Davidoff EJ, et al. The growing role of precision and personalized medicine for cancer treatment[J]. Technology (Singap World Sci), 2018, 6(3-4): 79-100.
|
| 5. |
González-Rivas JP, Seyedi SA, Mechanick JI. Artificial intelligence enabled lifestyle medicine in diabetes care: a narrative review[J]. Am J Lifestyle Med, 2025.
|
| 6. |
Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med, 2018, 379(15): 1416-1430.
|
| 7. |
Topol EJ. Individualized medicine from prewomb to tomb[J]. Cell, 2014, 157(1): 241-253.
|
| 8. |
白云丹, 田茜溪, 楊杰, 等. 新時代下慢病管理的分析與思考[J]. 中國衛生標準管理, 2022, 13(9): 39-41.
|
| 9. |
Hooda SM, Fields KK. Transitioning clinical practice guidelines into the electronic health record through clinical pathways[J]. Methods Mol Biol, 2021, 2194: 45-59.
|
| 10. |
Lancaster E, Wick E. Standardized care pathways as a means to improve patient safety[J]. Surg Clin North Am, 2021, 101(1): 49-56.
|
| 11. |
Institute of Medicine (US) Committee on Quality of Health Care in America. To err is human: building a safer health system[Z]. Washington (DC): National Academies Press (US), 2000.
|
| 12. |
Wennberg J, Gittelsohn None. Small area variations in health care delivery[J]. Science, 1973, 182(4117): 1102-1108.
|
| 13. |
Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population[J]. N Engl J Med, 2009, 360(5): 491-499.
|
| 14. |
World Health Organization. WHO guidelines for safe surgery 2009: safe surgery saves lives[Z]. 2009.
|
| 15. |
Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU[J]. N Engl J Med, 2006, 355(26): 2725-2732.
|
| 16. |
Burke T. The health information technology provisions in the American Recovery and Reinvestment Act of 2009: implications for public health policy and practice[J]. Public Health Rep, 2010, 125(1): 141-145.
|
| 17. |
Fisher JC, Godfried DH, Lighter-Fisher J, et al. A novel approach to leveraging electronic health record data to enhance pediatric surgical quality improvement bundle process compliance[J]. J Pediatr Surg, 2016, 51(6): 1030-1033.
|
| 18. |
Ong KY, Lee PSS, Lee ES. Patient-centred and not disease-focused: a review of guidelines and multimorbidity[J]. Singapore Med J, 2020, 61(11): 584-590.
|
| 19. |
Sheldrick RC. Randomized trials vs real-world evidence: how can both inform decision-making[J]. JAMA, 2023, 329(16): 1352-1353.
|
| 20. |
Velentgas P, Dreyer NA, Nourjah P, et al. Developing a protocol for observational comparative effectiveness research: a user's guide[Z]. Rockville (MD): Agency for Healthcare Research and Quality (US), 2013.
|
| 21. |
Lu C, Zha Q, Chang A, et al. Pattern differentiation in traditional Chinese medicine can help define specific indications for biomedical therapy in the treatment of rheumatoid arthritis[J]. J Altern Complement Med, 2009, 15(9): 1021-1025.
|
| 22. |
Marik PE, Linde-Zwirble WT, Bittner EA, et al. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database[J]. Intensive Care Med, 2017, 43(5): 625-632.
|
| 23. |
Peters-Sengers H, Butler JM, Uhel F, et al. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study[J]. Intensive Care Med, 2022, 48(1): 92-102.
|
| 24. |
Anaya JM, Duarte-Rey C, Sarmiento-Monroy JC, et al. Personalized medicine. Closing the gap between knowledge and clinical practice[J]. Autoimmun Rev, 2016, 15(8): 833-842.
|
| 25. |
National Human Genome Research Institute. Precision medicine[Z]. 2026.
|
| 26. |
Russo L, Lentini N, Soru L, et al. Randomized trials of 'personalized', 'individualized' and 'precision' interventions are very diverse and have low transparency and high bias[J]. J Clin Epidemiol, 2026, 196: 112338.
|
| 27. |
Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J]. Cancer Res, 1998, 58(13): 2825-2831.
|
| 28. |
Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia[J]. N Engl J Med, 2006, 355(23): 2408-2417.
|
| 29. |
Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol, 2011, 29(21): 2866-2874.
|
| 30. |
Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother[J]. Lancet, 2006, 368(9536): 704.
|
| 31. |
Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)[J]. Eur Heart J, 2018, 39(25): 2401-2408.
|
| 32. |
Elliott J, Bodinier B, Bond TA, et al. Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease[J]. JAMA, 2020, 323(7): 636-645.
|
| 33. |
Xu Y, Xia C, Tong S, et al. CanRisk-DB: an artificial intelligence-driven comprehensive database of cancer risk factors[J]. NPJ Precis Oncol, 2025, 9(1): 377.
|
| 34. |
Subbiah V. The next generation of evidence-based medicine[J]. Nat Med, 2023, 29(1): 49-58.
|
| 35. |
Formosa C, Chockalingam N, Papanas N, et al. Diabetic foot screening guidelines and the role of artificial intelligence: time to turn the tide[J]! Int J Low Extrem Wounds, 2024, 22: 15347346241234421.
|
| 36. |
Ellahham S. Artificial intelligence: the future for diabetes care[J]. Am J Med, 2020, 133(8): 895-900.
|
| 37. |
Murrin EM, Saad AF, Sullivan S, et al. Innovations in diabetes management for pregnant women: artificial intelligence and the internet of medical things[J]. Am J Perinatol, 2025, 42(12): 1540-1549.
|
| 38. |
Vincent JL, Singer M, Einav S, et al. Equilibrating SSC guidelines with individualized care[J]. Crit Care, 2021, 25(1): 397.
|
| 39. |
Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects[J]. BMJ, 2018, 363: k4245.
|
| 40. |
馬文昊, 王詩淳, 靳英輝, 等. 真實世界研究的發展與展望[J]. 中國循證心血管醫學雜志, 2023, 15(10): 1266-1271.
|
| 41. |
Samuel JP, Wootton SH, Tyson JE. N-of-1 trials: the epitome of personalized medicine[J]. J Clin Transl Sci, 2023, 7(1): e161.
|
| 42. |
Schad F, Thronicke A. Real-world evidence-current developments and perspectives[J]. Int J Environ Res Public Health, 2022, 19(16): 10159.
|
| 43. |
Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation[J]. Lancet, 2005, 365(9454): 176-186.
|
| 44. |
Lagakos SW. The challenge of subgroup analyses--reporting without distorting[J]. N Engl J Med, 2006, 354(16): 1667-1669.
|
| 45. |
Hernández AV, Boersma E, Murray GD, et al. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading[J]. Am Heart J, 2006, 151(2): 257-264.
|
| 46. |
Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty[J]. Circulation, 2005, 112: 2017-2021.
|
| 47. |
Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability[J]. Trials, 2009, 10: 37.
|
| 48. |
U. S. Food and Drug Administration. Real-world evidence[Z]. 2026.
|
| 49. |
National Institute for Health and Care Excellence. NICE real-world evidence framework[Z]. 2022.
|
| 50. |
Thelen H, Hennessy S. Characterizing treatment effect heterogeneity using real-world data[J]. Clin Pharmacol Ther, 2025, 117(5): 1209-1216.
|
| 51. |
Fourati A, Vergonjeanne M, Gellé T, et al. A practical guide to target trial emulation: connecting randomized trials and real-world data in cardiovascular research[J]. Eur J Prev Cardiol, 2026.
|
| 52. |
Simon-Tillaux N, Martin GL, Hajage D, et al. Conducting observational analyses with the target trial emulation approach: a methodological systematic review[J]. BMJ Open, 2024, 14(11): e086595.
|
| 53. |
Dang LE, Gruber S, Lee H, et al. A causal roadmap for generating high-quality real-world evidence[J]. J Clin Transl Sci, 2023, 7(1): e212.
|
| 54. |
Guyatt G, Sackett D, Taylor DW, et al. Determining optimal therapy-randomized trials in individual patients[J]. N Engl J Med, 1986, 314(14): 889-892.
|
| 55. |
Lee KM, Turner RM, Thwaites GE, et al. The personalised randomized controlled trial: evaluation of a new trial design[J]. Stat Med, 2023, 42(8): 1156-1170.
|
| 56. |
Klasnja P, Hekler EB, Shiffman S, et al. Microrandomized trials: an experimental design for developing just-in-time adaptive interventions[J]. Health Psychol, 2015, 34: 1220-1228.
|
| 57. |
Lorenzoni G, Petracci E, Scarpi E, et al. Use of sequential multiple assignment randomized trials (SMARTs) in oncology: systematic review of published studies[J]. Br J Cancer, 2023, 128(7): 1177-1188.
|